Inhibrx Biosciences, Inc. INBX R2KR3KPHARMA
Company Overview
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
Recent Developments
- Dec 2025 Revenue of $1.30M (+550.0% YoY); net profit $-140.06M.
- Trailing 12 Months Year-on-year growth — revenue +550.0%, earnings -108.3%.
- 5-Year Trend Long-term compounding — revenue CAGR -15.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -15.02% |
| 1 Year: | 550.00% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -108.30% |
Stock Price Performance
| 1 Year: | +414.09% |
| 6 Months: | +75.15% |
| 3 Months: | +39.26% |
| 1 Month: | +41.24% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)66.45 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -15.0% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | INBX Inhibrx Biosciences, Inc. R2KR3KPHARMA | 121.17 | -14.44 | $1.78B | 0.00% | -119.83% | - | -15.02% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 30.00K | 119.00K | 0 | 100.00K | 0 | 0 | 1.30M | 0 | - |
| Operating Income | - | -41.34M | -45.83M | -73.83M | -160.90M | -46.80M | -42.90M | -27.39M | -33.81M | -30.93M |
| Net Income | -48.92M | -47.05M | -51.79M | -78.71M | 1.86B | -43.86M | -43.31M | -28.65M | -35.26M | -33.44M |
| Diluted EPS | - | -4.31 | -4.39 | -5.77 | 125.48 | -2.84 | -2.80 | -1.85 | -2.28 | -2.15 |
| R&D Expense | - | 34.11M | 38.06M | 63.85M | 67.63M | 38.89M | 36.88M | 22.27M | 28.54M | 25.22M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 1.80M | 200.00K | 1.30M |
| Operating Income | -219.22M | -331.45M | -135.03M |
| Net Income | -241.36M | 1.69B | -140.06M |
| Diluted EPS | -20.48 | 112.62 | -9.04 |
| R&D Expense | 191.64M | 203.74M | 113.03M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | - | 307.89M | 180.77M | 146.48M |
| Total Equity | 58.06M | 43.50M | 133.58M | 7.99M |
| Cash & Equivalents | - | 277.92M | 152.60M | 124.22M |
| Long Term Debt | - | 206.97M | 0 | 100.56M |
| Total Liabilities | - | 264.39M | 47.18M | 138.49M |
| Current Liabilities | - | 56.31M | 40.73M | 33.80M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -193.31M | -194.41M | -129.79M |
| Investing Cash Flow | -4.59M | -2.60M | -28.00K |
| Financing Cash Flow | 201.96M | 71.68M | 101.45M |
| Capital Expenditure | -4.59M | -2.60M | -31.00K |
| Free Cash Flow | -197.90M | -197.01M | -129.82M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | - |
| Operating Margin % | -12,178.9% | -165,724.0% | -10,386.5% |
| Net Margin % | -13,408.9% | 843,786.0% | -10,773.5% |
| ROE % | -554.8% | 1,263.3% | -1,752.2% |
| ROCE % | -87.1% | -236.7% | -119.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Morgan Stanley | 8.89% | 1.31M | $161.43M |
| 2 | Perceptive Advisors Llc | 8.82% | 1.30M | $160.16M |
| 3 | Sanofi | 7.87% | 1.16M | $142.90M |
| 4 | Viking Global Investors, L.P. | 7.64% | 1.12M | $138.70M |
| 5 | HighTower Advisors, LLC | 5.92% | 870.55K | $107.43M |
| 6 | Bank of America Corporation | 5.72% | 841.14K | $103.81M |
| 7 | Blackrock Inc. | 5.61% | 825.97K | $101.93M |
| 8 | Schonfeld Strategic Advisors Llc | 4.74% | 697.59K | $86.09M |
| 9 | State Street Corporation | 4.35% | 640.46K | $79.04M |
| 10 | Vanguard Capital Management LLC | 3.35% | 492.48K | $60.78M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for INBX
INBX Stock Hit Record Highs: Retail Turns ‘Extremely Bullish’ On This Cancer Play - Stocktwits
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxNc2dmWVZaZ3hpV2p6NXFHci14amNhR2FlVWNfcGsxM0paSDlwUlRkS3V4ejlwbTBOUGhISGpnckFvVzQ3b3VjbEF6VVNTZmdFM1h1LVpsb0JkckxCWEJPWkI1MDlWWmJXUjktZ21RRm9uVXNiQ0V3bzk2bDVsRE5lLUo2NEY0dENFcF9RR3…
Cancer drug study results are due Sept. 8 from Inhibrx - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxPNVpNQ3dlRy1JYXhfZE5SRFdIRlpMQTZHcmFTeEQzMnBWZUpDOXVZVGlxMV9DNHJ3dVFaU1ZTUnpwcXAzb3NaWjNwblowM3Faak1BbnZ0cEIxZnhaNDRCLTE0VUEwam9mV2dmLTg2dkRpRHpnQjZhaWxXTkhDa1ZVQ2dxNXFRQ010X0dhRW…
Inhibrx Biosciences, Inc. Common Stock (INBX) Stock Price Today: $124.38 - Gotrade
<a href="https://news.google.com/rss/articles/CBMiV0FVX3lxTE9EcUlOQzNJcHlpTVpCT0pKR1diZHJqaDE4RE95Rmd4LTBfa2RNQjlHSHBWckx3YWplb1RHcHRNYW1fNXQ3cThBMENCTFRjdnVWRWMxQXhORQ?oc=5" target="_blank">Inhibrx Biosciences, Inc. Common Stock (INBX) Sto…
(INBX) Volatility Zones as Tactical Triggers - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxQR0R4X2twbUg3YWM1Q3ZCMGFyQTFsYzFoMVJOci1ERkE2Q2RmU3BYcVlkTXJpTXRQZmVXZDExNlc1N1g2ekE5dVJWQV9ObjZTRENfMkF3T1NSWWdsNTR2cGhkUGpNRDROWFBpWXJ2Q2FWREI1RWd3TWdudTlaT0NQc1BNWURkeHBJR2EzQ2…
Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million - PR Newswire
<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxQN254dmZNRlhXQzN2S2tJMHVHWXE5UlVHVlZEbmItSnY5WVp1UFpuVVZlRWhKb1UxZjlQeXVXOV9saTlxbU5XQjgtZFF5cjgzTTRHUENZSmc5WVRxTW9RM1FlZmc1aWlUX25MYzUwOUxLWWZQODRoRzVXVlgwRXRPbEJaVUI2VndUazBQbz…
Inhibrx Biosciences (INBX) Announces Positive Interim Results From Phase 2 Portion of HexAgon Study - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxOckpRLVpHNUJfNmFBMmNCU2d3MzNna2FjU2hVRV9YenpYdzg3MU9DREpRcENaVHF5eXJGR3NPbkprMTBjektHRHlzekhRTldod0xGMlREOUJxNUdWWThkRTVRN0RLQ2NVTFo5dkMzWHMyblp5SnlpVEV6aEcwZDhtbDIzT2xoT0tZUE9PTG…
INBX — Frequently Asked Questions
What is the current share price of Inhibrx Biosciences, Inc. (INBX)?
As of 2026-09-07 16:24 PDT, Inhibrx Biosciences, Inc. (INBX) trades at $121.17 on NasdaqGS. Its 52-week range is $23.00 to $141.84.
What is the market capitalisation of INBX?
Inhibrx Biosciences, Inc. (INBX) has a market capitalisation of $1.78B on NasdaqGS.
What is the P/E ratio of INBX?
INBX trades at a trailing price-to-earnings (P/E) ratio of -14.44. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is -61.57.
Is INBX a good stock to buy?
This page provides a data-driven analysis of Inhibrx Biosciences, Inc. (INBX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.